国药集团
SINOPHARM

國藥控股股份有限公司
SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT
PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD FOR THE FIRST QUARTER ENDED 31 MARCH 2026

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the "**Company**") dated 29 April 2026 (the "**Announcement**") in relation to the report for the first quarter ended 31 March 2026 of China National Accord Medicines Corporation Ltd. ("**Sinopharm Accord**"), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code for A shares: 000028; stock code for B shares: 200028).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited accounting data and financial indicators of Sinopharm Accord for the first quarter ended 31 March 2026 as set out in the Announcement.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".*

PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD

Whether it has retroactive adjustment or restatement on previous accounting data or not
□ Yes ☑No

Unit: Yuan
Currency: RMB

	The Reporting Period	**Same period of last year**	**Changes of this period over the same period of last year (%)**
Revenue	17,823,409,770.31	18,293,519,382.49	-2.57%
Net profit attributable to shareholders of the listed company	287,462,500.32	327,998,492.13	-12.36%
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	280,052,547.60	317,427,384.37	-11.77%
Net cash flow arising from operating activities	-2,935,333,476.40	-1,817,269,997.84	-61.52%
Basic earnings per share (Yuan/Share)	0.52	0.59	-11.86%
Diluted earnings per share (Yuan/Share)	0.52	0.59	-11.86%
Weighted average return on equity	1.53%	1.84%	Decreased by 0.31 percentage point

	At the end of the Reporting Period	**At the end of last year**	**Changes of this period over the same period of last year (%)**
Total assets	49,123,776,186.09	49,096,270,979.03	0.06%
Equity attributable to shareholders of listed company	18,897,425,775.89	18,609,963,275.57	1.54%

INFORMATION OF THE OPERATION RESULTS AND FINANCIAL SITUATION:

In the first quarter of 2026, Sinopharm Accord recorded revenue of RMB17.823 billion, representing a year-on-year decrease of 2.57%; net profit attributable to shareholders of the listed company of RMB287 million, representing a year-on-year decrease of 12.36%. Accordingly, the basic earnings per share recorded a year-on-year decrease of 11.86% , and the weighted average return on equity decreased by 0.31 percentage point.

In the first quarter of 2026, the distribution segment recorded revenue of RMB13.356 billion, representing a year -on-year decrease of 1.72%; net profit of RMB199 million, representing a year-on-year decrease of 13.60%. The decrease was mainly attributable to the changes in industry policies and intensified market competition, which resulted in a slight decline in sales revenue. In addition, delays in downstream collections prolonged the ageing of trade receivables, resulting in a year-on-year increase in provisions for bad debts, thereby reducing profit. The retail segment (i.e. "Sinopharm Holding Guoda Drugstore Co., Ltd." ("**Guoda Drugstore**")) recorded revenue of RMB4.739 billion, representing a year-on-year decrease of 4.89%; net profit of RMB5 million, representing a year-on-year increase of 15.42%. Impacted by changes in the influenza season and market competition, the sales revenue of Guoda Drugstore declined, but the rate of decline continued to narrow. In addition, Sinopharm Accord strengthened the management of loss- making businesses and adjusted its store network structure, which led to a reduction in relatively fixed costs such as labor cost and rental expenses and contributed to an increase in net profit.

In response to a complex and changing external environment, Sinopharm Accord will continue to uphold strategy-driven development, focus on high- quality development, deepen transformation and innovation, strengthen compliance and risk management, and continuously enhance operating quality and risk resilience, with a view to achieving stable and sustainable growth and laying a solid foundation for the commencement of the "15th Five- Year Plan".

By order of the Board
Sinopharm Group Co. Ltd.
Jin Bin
Chairman

Shanghai, the PRC
29 April 2026

As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.